Use of thalidomide for severe recurrent aphthous stomatitis: A multicenter cohort analysis

Medicine

Volumn 89, Issue 3, 2010, Pages 176-182

  Hello, Muriel ^a   Barbarot, Sébastien ^a   Bastuji Garin, Sylvie ^b   Revuz, Jean ^b   Chosidow, Olivier ^b  

^a HÔTEL DIEU   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADOLESCENT; ADULT; AGED; AMENORRHEA; APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEMORY DISORDER; MOOD CHANGE; MUCOSAL DRYNESS; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; RESPONSE TIME; SIDE EFFECT; SOMNOLENCE; TELEPHONE; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STOMATITIS, APHTHOUS; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952232267     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181dfca14     Document Type: Article

References (20)

1. Allen PF. Assessment of oral health related quality of life. Health Qual Life Outcomes. 2003;1:40.
2. Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, Poli F, Revuz J. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002;119:1020-1026.
3. Bonnetblanc JM, Royer C, Bedane C. Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology. 1996;193: 321-323.
4. Chattopadhyay A, Chatterjee S. Risk indicators for recurrent aphthous ulcers among adults in the US. Community Dent Oral Epidemiol. 2007;35:152-159.
5. Denman AM, Graham E, Howe L, Denman EJ, Lightman S. Low dose thalidomide treatment of Behcet-s syndrome. In: Wechsler B, Godeau P, eds. Behcet-s disease. Proceedings of the 6th International Conference on Behcet-s Disease, 30 June-1 July 1993; Paris, France.
6. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. Thalidomide et thromboses. Ann Dermatol Venereol. 2000;127:171-174.
7. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulcerations in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53:828-832.
8. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol. 1985;12:85-90.
9. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128: 443-450.
10. Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PD, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet. 1984;2:1424-1426.
11. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52:500-508.
12. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol. 1994;130:66-69.
13. Perri AJ III, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J. 2003;9:5.
14. Revuz J, Guillaume JC, Janier M, Hans P, Marchand C, Souteyrand P, Bonnetblanc JM, Claudy A, Dallac S, Klene C, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126:923-927.
15. Rogers RS III. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg. 1997;16: 278-283.
16. Scully C. Aphthous ulceration. NEngl JMed. 2006;355:165-172.
17. Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg. 2008;46:198-206.
18. Torras H, Lecha M, Mascaro JM. Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis [letter]. Arch Dermatol. 1982;118:875.
19. Verpilleux MP, Bastuji-Garin S, Revuz J. Comparative analysis of severe aphthosis and Behcet's disease: 104 cases. Dermatology. 1999;198: 247-251.
20. de Wazieres B, Gil H, Magy N, Berthier S, Vuitton DA, Dupond JL. Traitement de l'aphtose recurrente par thalidomide: etude pilote chez 17 patients. Rev Med Interne. 1999;20:567-570.